OncoSec Medical Incorporated (ONCSQ)
OTCMKTS: ONCSQ · Delayed Price · USD
0.0001
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market open
OncoSec Medical Employees
As of July 31, 2022, OncoSec Medical had 41 total employees, including 40 full-time and 1 part-time employees. The number of employees decreased by 17 or -29.31% compared to the previous year.
Employees
41
Change (1Y)
-17
Growth (1Y)
-29.31%
Revenue / Employee
n/a
Profits / Employee
-$716,728
Market Cap
596.00
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
ONCSQ News
- 1 year ago - OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program - PRNewsWire
- 1 year ago - OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program - PRNewsWire
- 1 year ago - OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment - PRNewsWire
- 1 year ago - OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 - PRNewsWire